Abstract
Parkinson’s disease is a common neurodegenerative disease affecting the movement and well-being of most elderly. The manifestations of Parkinson’s disease often include resting tremor, stiffness, bradykinesia, and muscular rigidity. The typical hallmark of Parkinson’s disease is the destruction of neurons in the substantia nigra and the presence of Lewy bodies in different compartments of the central nervous system. Due to various limitations to the currently available treatments, immunotherapies have emerged to be the new approach to Parkinson’s disease treatment. This approach shows some positive outcomes on the efficacy by removing the aggregated species of alpha-synuclein, which is believed to be one of the causes of Parkinson’s disease. In this review, an overview of how alpha-synuclein contributes to Parkinson’s disease and the effects of a few new immunotherapeutic treatments, including BIIB054 (cinpanemab), MEDI1341, AFFITOPE, and PRX002 (prasinezumab) that are currently under clinical development, will be discussed.
Keywords: Parkinson's disease, alpha-synuclein, immunotherapies, BIIB054, MEDI1341, AFFITOPE PRX002.
CNS & Neurological Disorders - Drug Targets
Title:Immunotherapies for Parkinson’s Disease: Progression of Clinical Development
Volume: 20 Issue: 9
Author(s): Jet Shee Teng, Yin Yin Ooi, Soi Moi Chye, Anna Pick Kiong Ling and Rhun Yian Koh*
Affiliation:
- Division of Applied Biomedical Science and Biotechnology, School of Health Science, International Medical University, Kuala Lumpur,Malaysia
Keywords: Parkinson's disease, alpha-synuclein, immunotherapies, BIIB054, MEDI1341, AFFITOPE PRX002.
Abstract: Parkinson’s disease is a common neurodegenerative disease affecting the movement and well-being of most elderly. The manifestations of Parkinson’s disease often include resting tremor, stiffness, bradykinesia, and muscular rigidity. The typical hallmark of Parkinson’s disease is the destruction of neurons in the substantia nigra and the presence of Lewy bodies in different compartments of the central nervous system. Due to various limitations to the currently available treatments, immunotherapies have emerged to be the new approach to Parkinson’s disease treatment. This approach shows some positive outcomes on the efficacy by removing the aggregated species of alpha-synuclein, which is believed to be one of the causes of Parkinson’s disease. In this review, an overview of how alpha-synuclein contributes to Parkinson’s disease and the effects of a few new immunotherapeutic treatments, including BIIB054 (cinpanemab), MEDI1341, AFFITOPE, and PRX002 (prasinezumab) that are currently under clinical development, will be discussed.
Export Options
About this article
Cite this article as:
Teng Shee Jet, Ooi Yin Yin, Chye Moi Soi , Ling Pick Kiong Anna and Koh Yian Rhun *, Immunotherapies for Parkinson’s Disease: Progression of Clinical Development, CNS & Neurological Disorders - Drug Targets 2021; 20 (9) . https://dx.doi.org/10.2174/1871527320666210526160926
DOI https://dx.doi.org/10.2174/1871527320666210526160926 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Cytotoxicity of Titanocene Y Against CAKI-1 Cells: An In Vitro Formulation Study
Letters in Drug Design & Discovery Searching the Staphylococcal Toxic Shock Syndrome Toxin -1 in Septic Children with negative Cultures: A Comparative Study in Tehran, Iran
Infectious Disorders - Drug Targets ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases
Current Pharmaceutical Design Dyslipidemia Treatment and Cardiovascular Disease in the Renal Patient
Current Pharmaceutical Design New Insights into the Surgical Management of Tetralogy of Fallot: Physiological Fundamentals and Clinical Relevance
Current Pediatric Reviews Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism Risk Factors for Upper GI Damage in Low-Dose Aspirin Users and the Interaction Between <i>H. pylori</i> Infection and Low-Dose Aspirin Use
Current Pharmaceutical Design Drug Acyl Glucuronides: Reactivity and Analytical Implication
Current Pharmaceutical Analysis TNF-α and Ghrelin: Opposite Effects on Immune System, Metabolism and Mental Health
Protein & Peptide Letters ECG for Cardiovascular Diseases Using Soft Computing Algorithms
Current Signal Transduction Therapy rDNA Mediated Bioconjugates: Fusion Proteins and their Intended Use in Medicine
Current Topics in Medicinal Chemistry Secondary Stroke Prevention in Patients with Cryptogenic Stroke and Patent Foramen Ovale
Vascular Disease Prevention (Discontinued) Recent Progress in the Development of HIV-1 Entry Inhibitors: From Small Molecules to Potent Anti-HIV Agents
Current Topics in Medicinal Chemistry Clinical Pharmacology of Trastuzumab
Current Clinical Pharmacology Pharmacological Regulators of Intracellular Calcium Release Channels
Current Pharmaceutical Design Physical Function and Exercise in Older Patients with Cardiovascular and Respiratory Conditions
Current Pharmaceutical Design The Right Ventricle: Biologic Insights and Response to Disease: Updated
Current Cardiology Reviews COPD Phenotypes and Biomarkers: Introducing Personalised Medicine
Current Respiratory Medicine Reviews TNF α Signaling Beholds Thalidomide Saga: A Review of Mechanistic Role of TNF-α Signaling Under Thalidomide
Current Topics in Medicinal Chemistry T-type Calcium Channels in Health and Disease
Current Medicinal Chemistry